tbuckley/cabot-search huggingface dataset:
Hepatitis C virus infection in medical personnel after needlestick accident
Authors: T Mitsui
Journal: Hepatology (1992)

Hepatitis C virus infections in medical personnel after needlestick accidents have been documented generally by detection of seroconversion to a hepatitis C virus nonstructural region antigen, c100-3 (a marker of infection). We tested for hepatitis C virus core-derived antibodies and genomic RNA in addition to c100-3 antibody in 159 cases of needlestick exposure that did not involve patients positive for HBsAg. Of these we found 68 cases with index patients positive for both hepatitis C virus RNA and antibodies and members negative for antibodies to HCV core or c100-3 before the needlestick accidents. Seven of these medical personnel became infected with hepatitis C virus after the accidents. Their hepatitis was generally subclinical or self-limited and transient, except for one patient in whom liver enzyme elevation persisted along with the antibodies. In our study, the risk of hepatitis C virus transmission from a single needlestick accident with hepatitis C virus RNA–positive blood was 10%, considerably higher than the 4% estimated in a previous study. We found that donor blood with antibody to an hepatitis C virus core-derived peptide with enzyme-linked immunosorbent assay optical densities greater than 2.0 carried a significant risk of transmitting hepatitis C virus to needlestick victims. No hepatitis C virus seroconversions occurred in medical personnel exposed to hepatitis C virus antibody– negative or hepatitis C virus RNA–negative blood; however, one such exposure resulted in a very mild non-A, non-B, non-C hepatitis. (HEPATOLOGY 1992;16:1109–1114.)
Seventh International Cyclic Nucleotide Conference
Journal: JNCI Journal of the National Cancer Institute (1979)

Journal Article Seventh International Cyclic Nucleotide Conference Get access JNCI: Journal of the National Cancer Institute, Volume 63, Issue 4, October 1979, Page 1105, https://doi.org/10.1093/jnci/63.4.1105-c Published: 01 October 1979
Questions and Answers.
Journal: JAMA (1884)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Blinatumomab
Authors: Talha Badar, Aniko Szabo, Anjali S. Advani, Martha Wadleigh, Shukaib Arslan, Muhammad Khan, Ibrahim Aldoss, Caitlin Siebenaller, Elizabeth Schultz, Mehrdad Hefazi, Rory M Shallis, Ilana Yurkiewicz, Nikolai A. Podoltsev, Anand Ashwin Patel, Emily K Curran, Suresh Kumar Balasubramanian, Jay Yang, Ryan J. Mattison, Madelyn Burkart, Shira Dinner, Michaela Liedtke, Mark Litzow, Ehab L. Atallah
Journal: Blood (2019)
BOOK REVIEWS
Authors: G. R. MORROW, P. M. BLACK
Journal: JNCI Journal of the National Cancer Institute (1990)

BOOK REVIEWS Get access Handbook of Psychooncology: Psychological Care of the Patient With Cancer . Jimmie C. Holland , Julia H. Rowland , eds New York : Oxford University Press , 1989 , 785 pp. $95. GARY R. MORROW, GARY R. MORROW Behavioral Medicine Unit University of Rochester Cancer Center601 Elmwood Ave., Box 704 Rochester, NY 14642 Search for other works by this author on: Oxford Academic PubMed Google Scholar PETER M. BLACK PETER M. BLACK Behavioral Medicine Unit University of Rochester Cancer Center601 Elmwood Ave., Box 704 Rochester, NY 14642 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 82, Issue 9, 2 May 1990, Page 789, https://doi.org/10.1093/jnci/82.9.789 Published: 02 May 1990
Focused Cardiac Ultrasonography for Left Ventricular Systolic Function
Authors: Gabriel Prada, Ashley V. Fritz, Mariana Restrepo-Holguín, Pramod K. Guru, José L. Díaz-Gómez
Journal: New England Journal of Medicine (2019)

This video presents a practical method for conducting focused cardiac ultrasonography, a qualitative or semiquantitative means of assessing cardiac size, structure, and function at the bedside. The video shows how to perform visual assessment of left ventricular systolic function.
Cephalexin for susceptible bacteriuria in afebrile, long-term catheterized patients
Authors: J. W. Warren
Journal: JAMA (1982)

Patients with long-term indwelling urethral catheters are subject to acute and long-term complications of bacteriuria. To evaluate the common practice of short-course antibiotic therapy in such patients, we performed a randomized controlled trial of ten-day courses of cephalexin monohydrate repeated whenever a susceptible bacteriuria was present. We observed 17 cephalexin group patients for 545 patient-weeks (160 cephalexin courses) and 18 control group patients for 477 patient-weeks. Throughout the study, the groups were comparable in regard to incidence and prevalence of bacteriuria, number of bacterial strains per weekly urine specimen, incidence of febrile days, and incidence of obstructed catheters. In the cephalexin group, the frequency of fever during periods when antibiotics were being used was similar to that during periods when antibiotics were not being used. More cephalexin-resistant bacteria were isolated from cephalexin group patients. Routine treatment with cephalexin of asymptomatic long-term catheterized patients, even for susceptible organisms, does not seem to be warranted. (<i>JAMA</i>1982;248:454-458)
EDUCATION AND INSANITY.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
July 1976, Vol. 57, No.1
Journal: JNCI Journal of the National Cancer Institute (1977)

July 1976, Vol. 57, No.1 Get access JNCI: Journal of the National Cancer Institute, Volume 58, Issue 3, March 1977, Page 819, https://doi.org/10.1093/jnci/58.3.918-a Published: 01 March 1977
Fortieth Annual Symposium on Fundamental Cancer Research
Journal: JNCI Journal of the National Cancer Institute (1987)

Fortieth Annual Symposium on Fundamental Cancer Research Get access JNCI: Journal of the National Cancer Institute, Volume 79, Issue 2, August 1987, Page 401, https://doi.org/10.1093/jnci/79.2.401-b Published: 01 August 1987
Handbook of Diseases of the Skin
Journal: JAMA (1949)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Memoranda on the International Standardization of Therapeutic Sera and Bacterial Products.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
US military forces and emergency international humanitarian assistance. Observations and recommendations from three recent missions
Authors: T. W. Sharp
Journal: JAMA (1994)

THE US MILITARY has a long tradition of providing emergency humanitarian relief after armed confrontation and disaster, and often to peoples of other nations. After World War II and the Vietnam War, as well as after many smaller conflicts, US forces provided supplies and medical services to thousands of refugees and displaced persons.<sup>1-3</sup>Following earthquakes in Peru (1970) and Nicaragua (1972), flooding in Sudan (1988), volcanic eruption in the Philippines (1990), and tropical cyclones in East Bengal (1970), Sri Lanka (1978), and Bangladesh (1991), the US military dispatched medical teams and relief supplies to assist disaster victims.<sup>4-7</sup>Also, US military forces participated for humanitarian purposes in the United Nations (UN) intervention in Korea and more recently in Kurdistan<sup>8</sup>and Somalia.<sup>9</sup>A US military hospital is currently in Zagreb, Croatia, to provide medical care for UN peacekeeping forces in the former Yugoslavia and possibly to displaced persons
Current Status of Palliative vs. Corrective Procedures in Congenital Heart Surgery
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
INFANT BEHAVIOUR
Authors: R. S. Illingworth
Journal: BMJ (1962)

<h3>Abstract</h3> <h3>Background</h3> Long COVID—also known as post-acute sequelae of COVID-19 or PASC—is a systemic syndrome affecting a large number of persons in the aftermath of the pandemic. Cognitive dysfunction (or brain fog) is one of its most common manifestations of PACS, and there are no effective interventions to mitigate it. Home-based personalized computerized cognitive training (CCT), which has shown effectiveness to improve other conditions, could offer hope to relieve the cognitive dysfunction in people with a previous history of COVID-19. <h3>Objective</h3> To evaluate the feasibility and potential benefit of a personalized CCT intervention to improve cognitive function among people living with PACS. <h3>Methods</h3> Adult individuals who self-reported cognitive dysfunction more than 3 months after a diagnosis of COVID-19 were recruited through an online platform designed for the study. Those who were eligible assessed their general cognitive function before completing as many cognitive daily training sessions as they wished during an 8-week period, using a personalized CCT application at home. The sessions included gamified tasks that tapped into five cognitive domains (attention, coordination, memory, perception and reasoning) and were tailored to the specific cognitive strengths and weaknesses detected at each point. At the end of this period, participants repeated the general cognitive function assessment. The differences between the scores at 8 weeks and baseline was the main outcome, complemented with analyses of the changes based on the participants’ age, training time, self-reported health level at baseline and time since the initial COVID-19 infection. Participants’ cognitive assessment scores were also computed in terms of percentiles according to the normative database of the test, considering their corresponding age- and gender-based reference sample. <h3>Results</h3> The participants had significant cognitive dysfunction at baseline, even though 80% of them had had the initial episode of COVID-19 more than a year before enrolling in the study. Eighty nine percent reported negative levels of self-reported health at baseline. On average, 51 training sessions (range: 10 to 251) were completed over a mean time of 435 minutes (range 78 to 2448). Most of the participants obtained higher scores after CCT in each of the domains as compared with baseline (attention: 81% of the sample; memory: 86%; coordination: 82%; perception: 88%; reasoning: 77%). The magnitude of the score increase at post-test was high across domains (attention: 31% of change; memory: 37%; coordination: 52%; perception: 42%; reasoning: 26%). Following CCT, there were also improvements in the percentile data in all the domains (attention: 14 points; memory: 18 points; coordination: 18 points; perception: 17 points; reasoning: 11 points). <h3>Conclusions</h3> This study suggests that a self-administered CCT based on gamified cognitive tasks could be an effective way to ameliorate cognitive dysfunction in persons with PASC.
Correction: Retinoblastoma
Authors: Helen Dimaras, Timothy W. Corson, David Cobrinik, Abby White, Junyang Zhao, Francis L. Munier, David H. Abramson, Carol L. Shields, Guillermo L. Chantada, Festus Njuguna, Brenda L. Gallie
Journal: Nature Reviews Disease Primers (2015)
Jaundice after repeated exposure to halothane: a further analysis of reports to the Committee on Safety of Medicines.
Authors: W H Inman, W W Mushin
Journal: BMJ (1978)

Aanalysis of data derived from 170 reports of jaundice developing after anaesthesia with halothane received after January 1974 confirmed the relations between multiple exposure to halothane and jaundice and between the number of exposures and the rapidity with which jaundice develops after exposure. When these reports were combined with 130 received earlier complete anaesthetic histories were available for 251 patients, 205 (82%) of whom had been exposed to halothane more than once; of these patients, 154 (75%) had been exposed more than once within 28 days. Altogether 139 (46%) of the 300 patients died.
Steroid drugs
Authors: Guy Williams-Ashman
Journal: JAMA (1963)

This thick book surveys the chemistry and physiological actions of steroids primarily from the standpoint of their pharmaceutical applications. The first two sections deal with the history, technology, and economics of industrial steroid research. An excellent account is given of methods for the isolation of raw materials used in the manufacture of steroids of major commercial importance, and of the individual chemical and microbiological reactions employed in the various synthetic processes. The treatment is authoritative and up-to-date, and the text is very well illustrated with structural formulae. The succeeding section attempts to summarize a vast body of experimental and clinical research on the influence of steroids on sexual physiology and homeostasis, and also on a wide variety of disease processes and other states, ranging from cancer and atherosclerosis to aging and beauty culture. Much emphasis is placed on chemical modifications of natural hormones which may elicit qualitatively different pharmacodynamic effects.
Azathioprine-induced pure red blood cell aplasia
Authors: C. W. Old
Journal: JAMA (1978)

Pure RBC aplasia developed in two renal transplant recipients who were receiving long-term azathioprine therapy. With substitution of cyclophosphamide therapy for azathioprine, erythroid hyperplasia and reticulocytosis developed at three weeks in one patient and at three months in the other. Selective erythroid toxic reaction is a potential problem that must be considered when anemia develops in patients receiving long-term azathioprine therapy. (<i>JAMA</i>240:552-554, 1978)
Error in Figure Presentation
Journal: JAMA Oncology (2016)

Amylou C. Dueck, PhD; Tito R. Mendoza, PhD; Sandra A. Mitchell, PhD, CRNP, AOCN; Bryce B. Reeve, PhD; Kathleen M. Castro, RN, MS, AOCN; Lauren J. Rogak, MA; Thomas M. Atkinson, PhD; Antonia V. Bennett, PhD; Andrea M. Denicoff, MS, RN, ANP; Ann M. O'Mara, PhD, RN, FAAN; Yuelin Li, PhD; Steven B. Clauser, PhD, MPA; Donna M. Bryant, MSN, ANP-BC, OCN, CCRC; James D. Bearden III, MD, FACP; Theresa A. Gillis, MD; Jay K. Harness, MD; Robert D. Siegel, MD, FACP; Diane B. Paul, AAS; Charles S. Cleeland, PhD; Deborah Schrag, MD, MPH; Jeff A. Sloan, PhD; Amy P. Abernethy, MD, PhD; Deborah W. Bruner, RN, PhD, FAAN; Lori M. Minasian, MD, FACP; Ethan Basch, MD, MSc; for the National Cancer Institute PRO-CTCAE Study Group
&lt;TITLE&gt;Pulmonary Embolism&lt;/TITLE&gt;
Journal: JAMA (2001)

a public service of JAMA.The information and recommendations appearing on this page are appropriate in most instances, but they are not a substitute for medical diagnosis.For specific information concerning your personal medical condition, JAMA and the AMA suggest that you consult your physician.This page may be reproduced noncommercially by physicians and other health care professionals to share with patients.Any other reproduction is subject to AMA approval.
Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.
Authors: Keun Wook Lee, Young-Hyuck Im, Keun Seok Lee, Jae Yong Cho, Do-Youn Oh, Hyun Cheol Cheol Chung, Yee Chao, Li-Yuan Bai, Chia Jui Yen, In-Ho Kim, Sang Cheul Oh, Chia-Chi Lin, Jin Wang, Xin Wang, Huiyan Li, Yen-Yang Chen, Yoon-Koo Kang
Journal: Journal of Clinical Oncology (2021)

TPS2656 Background: Zanidatamab is a novel HER2-targeted antibody that binds two distinct extracellular domains of HER2, allowing for multiple mechanisms of action including enhanced binding, clustering, receptor internalization and downregulation; this results in inhibition of ligand-dependent and -independent proliferation and potent activation of antibody-dependent cellular cytotoxicity. Zanidatamab monotherapy is well tolerated and has shown promising anti-tumor activity in patients (pts) with pre-treated advanced HER2-positive cancers, and was well tolerated in a Phase I trial (NCT02892123). Tislelizumab is an investigational anti-programmed death-1 (PD-1) antibody engineered to minimize binding of FcγR on macrophages in order to abrogate antibody-dependent phagocytosis, which is a potential mechanism of T-cell clearance and resistance to anti-PD-1 therapy. Tislelizumab is well tolerated and has anti-tumor activity alone and in combination with chemotherapy in pts with advanced solid tumors. The highly immunogenic nature of HER2 tumors has led to the development of therapies combining anti-HER2 therapies with immune checkpoint blockade. Methods: This open-label, two cohort Phase 1B/2 study (NCT04276493) is designed to evaluate zanidatamab as a first-line therapy with chemotherapy in pts with HER2-positive metastatic breast cancer (mBC; cohort 1) or with chemotherapy + tislelizumab in pts with HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma (GC/GEJC; cohort 2). Weight-based dosing (cohorts 1a and 2a) and flat dosing (cohorts 1b and 2b) regimens of zanidatamab are being investigated. In cohort 1 (n = 20), pts with treatment-naïve HER2-positive (IHC3+ or ISH amplified) mBC will receive intravenous (IV) zanidatamab 30 mg/kg (cohort 1a) or 1800 mg (cohort 1b), plus IV docetaxel 75 mg/m 2 once every 3 weeks (Q3W). In cohort 2 (n = 30), treatment-naïve pts with HER2-positive (IHC3+ or IHC2+ with ISH amplification) advanced GC/GEJC will receive IV zanidatamab 30 mg/kg (cohort 2a), or 1800 mg (pts &lt; 70kg; cohort 2b) or 2400 mg (pts ≥ 70kg; cohort 2b), plus IV tislelizumab 200 mg and chemotherapy (CAPOX regimen: oral capecitabine 1000 mg/m 2 twice daily [days 1–14] and IV oxaliplatin 130 mg/m 2 [day 1]) Q3W. For cohort 2 there is a six pt safety lead-in phase, followed by dose expansion after approval by the safety monitoring committee. Primary endpoints are the safety profile and objective response rate. Secondary endpoints include duration of response, time to response, progression-free survival, disease control rate, and overall survival. Clinical trial information: NCT02892123.